Deutsche Bank cuts Schott Pharma stock rating to Hold

Published on 10/27/2026 at 12:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue hit EUR 281.76 million, up 9.87 percent year over year. Schott Pharma stock costs EUR 25.50 on October 27, 2026, matching Xetra.

Analyst change and operating growth

Deutsche Bank moved its rating to Hold and raised the target to EUR 25.00 on October 9, 2026.
Third-quarter revenue reached EUR 281.76 million, up 9.87 percent year over year.
Schott Pharma stock trades at EUR 25.50 at 12:46 p.m. CEST at Lang & Schwarz on October 27, 2026, 0.00 percent versus the Xetra close of October 26, 2026.

Schott Pharma, DE000A3ENQ51, Illustration mit AI erstellt.

Schott Pharma (ISIN DE000A3ENQ51) is at EUR 25.50 at Lang & Schwarz on October 27, 2026, matching the Xetra close of October 26, 2026. Deutsche Bank cut its rating to Hold and raised its price target from EUR 23.00 to EUR 25.00 on October 9, 2026, according to MarketScreener.

Third-quarter growth supports the case

Schott Pharma reported revenue of EUR 281.76 million for the quarter ended June 30, 2026, up 9.87 percent from EUR 256.46 million a year earlier. Earnings per share fell to EUR 0.26 from EUR 0.30 in the prior-year quarter, while operating income reached EUR 53.26 million, based on the reported financial statements for the period.

The revenue comparison points to continued demand for pharmaceutical containment and delivery systems, but the earnings-per-share decline makes profitability the key counterweight. The company supplies syringes, cartridges, vials and ampoules for injectable medicines, a business profile described by SCHOTT Pharma.

Three dated steps in the stock story

On August 12, 2026, third-quarter revenue reached EUR 281.76 million; on September 15, 2026, JPMorgan initiated coverage with a EUR 27.10 target; and on October 9, 2026, Deutsche Bank moved to Hold while lifting its target to EUR 25.00. The Deutsche Bank action and target were reported by MarketScreener, while the third-quarter figures were reported by finanzen.ch.

Which dates come next?

SCHOTT Pharma lists the BNP Midcap CEO Conference for November 17, 2026, the LBBW German Company Day for November 18, 2026, and the Jefferies Global Healthcare Conference for November 19, 2026, on its investor-relations calendar. Those dates give investors the next scheduled opportunities to hear about strategy and demand.

Stock holds the 25.50 mark

The stock's 52-week range was EUR 12.62 to EUR 26.20 as of October 26, 2026, placing the current euro quotation EUR 0.70 below the reported high. At Lang & Schwarz, Schott Pharma was trading at EUR 25.50 on October 27, 2026 at 12:46 p.m. CEST, 0.00 percent versus the Xetra close of October 26, 2026 at EUR 25.50. The further course of trading is shown by the continuously updated real-time quote of Schott Pharma stock.